"The clinical trials are progressing extremely wel

"The clinical trials are progressing extremely well and right on schedule," commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. "As we await the lab reports, it's very encouraging that we have not seen any of the toxic side effects that are commonly associated with chemotherapy at this point. Many new drugs demonstrate toxicity immediately, so I interpret the information on Kevetrin™ with a great deal of optimism.

We are excited for the upcoming weeks when the next cohort, in which dosing levels will be doubled, may provide us even greater insight on what we believe is the most exciting oncologic drug in development today."